These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38469106)

  • 21. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
    Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
    J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Practices and Gaps in Management of Dyslipidemia in Type 2 Diabetes Mellitus (T2DM) in Accordance with American Diabetes Association (ADA) Guidelines: A Subset Analysis from a Real-World, Cross-Sectional Observational Study (LEADD Study).
    Das AK; Saboo B; Unnikrishnan AG
    Diabetes Metab Syndr Obes; 2021; 14():2693-2700. PubMed ID: 34163197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
    Lee YJ; Cho JY; You SC; Lee YH; Yun KH; Cho YH; Shin WY; Im SW; Kang WC; Park Y; Lee SY; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    Eur Heart J; 2023 Mar; 44(11):972-983. PubMed ID: 36529993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of statins in patients with type 2 diabetes mellitus: the practice in a lower middle income South Asian country.
    Matthias AT; Kaushalya J; Somathilake G; Garusinghe C
    Int J Diabetes Dev Ctries; 2023 Jun; 43(3):405-411. PubMed ID: 35822081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy.
    Habte ML; Melka DS; Degef M; Menon MKC; Yifter H; Feyisa TO
    Diabetes Metab Syndr Obes; 2020; 13():763-773. PubMed ID: 32256093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia.
    Regassa LD; Tola A; Ayele Y
    Front Public Health; 2020; 8():532719. PubMed ID: 33614562
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease.
    Mahtta D; Ramsey DJ; Al Rifai M; Nasir K; Samad Z; Aguilar D; Jneid H; Ballantyne CM; Petersen LA; Virani SS
    JAMA Netw Open; 2020 Aug; 3(8):e2011051. PubMed ID: 32816031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
    Thanassoulis G; Sniderman AD; Pencina MJ
    JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
    Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
    Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnitude of glycemic control and its associated factors among patients with type 2 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
    Tekalegn Y; Addissie A; Kebede T; Ayele W
    PLoS One; 2018; 13(3):e0193442. PubMed ID: 29505602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.
    Dorsch MP; Lester CA; Ding Y; Joseph M; Brook RD
    J Am Heart Assoc; 2019 Nov; 8(22):e014709. PubMed ID: 31707943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.
    Byrne P; Cullinan J; Murphy C; Smith SM
    BMJ Open; 2018 Feb; 8(2):e018524. PubMed ID: 29439070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
    Ramos R; Comas-Cufí M; Martí-Lluch R; Balló E; Ponjoan A; Alves-Cabratosa L; Blanch J; Marrugat J; Elosua R; Grau M; Elosua-Bayes M; García-Ortiz L; Garcia-Gil M
    BMJ; 2018 Sep; 362():k3359. PubMed ID: 30185425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa.
    Pitso L; Mofokeng TRP; Nel R
    BMC Endocr Disord; 2021 Aug; 21(1):159. PubMed ID: 34365977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.